BioSpace News Archive

iXensor, the pioneer of mobile health, today announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder.

BioArctic AB’s partner Eisai announced that an article about long-term health outcomes of the investigational anti-amyloid-beta protofibril antibody lecanemab in people living with early Alzheimer’s disease, using disease modeling, was published in the peer-reviewed journal Neurology and Therapy.

Bionter AG, experts in sub-visible particle testing, announced the completion of a $3 million Series Seed financing from Dynamk Capital.

The exciting translational data presented on BI-1808 at AACR clearly show why we are so enthusiastic about our ongoing clinical studies in solid tumors.

Our strong finish of 2021 is now followed by a first quarter of 2022 with considerable growth for both order intake and net sales. We increased the order book to 91.4 (72.9) MSEK compared to the end of 2021 (87.1) MSEK.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for filing the Company’s resubmitted New Drug Application for PEDMARKᵀᴹ for the prevention of platinum-induced ototoxicity in pediatric patients one month to <18 years of age with localized, non-metastatic, solid tumors.

BeiGene announced the Independent Data Monitoring Committee determined at a pre-planned interim analysis that RATIONALE 306, a global Phase 3 trial of tislelizumab in combination with chemotherapy, had met the study’s primary endpoint of overall survival in patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma.

Xenetic Biosciences, Inc. announced that it has entered into exclusive license and sublicense agreements with CLS Therapeutics to develop its interventional DNase based oncology platform, which is aimed at improving outcomes of existing treatments, including immunotherapies.

Boston Scientific Corporation generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for the first quarter of 2022.